Page last updated: 2024-08-24

gemcitabine and melphalan

gemcitabine has been researched along with melphalan in 38 studies

Research

Studies (38)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (36.84)	29.6817
2010's	21 (55.26)	24.3611
2020's	3 (7.89)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE	1
Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I	1
Albella, B; Bueren, JA; Keyes, KA; Parchment, RE; Segovia, JC	1
Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K	1
Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Urano, M	1
Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE; Vermorken, JB	1
Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS	1
Cottler-Fox, M; Fassas, A; Fenton, R; French, T; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Murthy, A; Philips, GL; Rapoport, AP; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tan, M; Tricot, G	1
Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R	1
Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E	1
Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L	1
Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A	1
Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P	1
Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L	1
Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G	1
Bagnobianchi, A; Bingham, JP; Craddock, C; Hartley, JA; Hochhauser, D; Kiakos, K; Ledermann, JA; Lowe, HL; Newton, C; Spanswick, VJ	1
Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Champlin, R; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Liu, P; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Valdez, B	1
Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E	1
Balza, E; Borsi, L; Carnemolla, B; Castellani, P; Mortara, L; Orecchia, P	1
Blazar, BR; Chandler, P; Ding, ZC; Huang, L; Krasinski, A; Lemos, H; Liu, K; Lu, X; Mack, M; Mellor, AL; Munn, DH; Walters, M; Yu, M; Zhou, G	1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC	1
Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T	1
Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA	1
Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC	1
Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A	1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W	1
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC	1
Galvez-Silva, J; Hernandez, F; Liu, D; Maher, OM; Nieto, Y; Park, M; Tewari, P	1
Gahrton, G	1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC	1
Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R	1
Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC	1
Armand, P; Fisher, DC; Jacobsen, ED; Jacobson, C; Jeter, E; Kim, HT	1

Reviews

1 review(s) available for gemcitabine and melphalan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

6 trial(s) available for gemcitabine and melphalan

Article	Year
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome	2001
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous	2007
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Radionuclide Imaging; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2013
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Vorinostat	2015
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult	2018

Other Studies

31 other study(ies) available for gemcitabine and melphalan

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. European journal of medicinal chemistry, 2010, Volume: 45, Issue:4 Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water	2010
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors	2000
Latent hematopoietic stem cell toxicity associated with protracted drug administration. Experimental hematology, 2001, Volume: 29, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Colony-Forming Units Assay; Crosses, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematopoiesis; Hematopoietic Stem Cells; Injections, Intraperitoneal; Male; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylenediamines; Time Factors	2001
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bone marrow transplantation, 2001, Volume: 28, Issue:9 Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine	2001
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Annals of surgical oncology, 2003, Volume: 10, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; Hyperthermia, Induced; Irinotecan; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Oxaliplatin; Paclitaxel	2003
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases. The Journal of thoracic and cardiovascular surgery, 2005, Volume: 130, Issue:1 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Male; Melphalan; Rats; Rats, Inbred Strains; Tumor Cells, Cultured	2005
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20 Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays	2005
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone marrow transplantation, 2006, Volume: 37, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous	2006
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation Cancer, 2006, Jan-15, Volume: 106, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome	2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. American journal of hematology, 2007, Volume: 82, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine	2007
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma]. Medicina clinica, 2012, Dec-01, Volume: 139, Issue:13 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine	2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2012
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Experimental hematology, 2012, Volume: 40, Issue:10 Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins	2012
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC cancer, 2012, Sep-28, Volume: 12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histones; Homologous Recombination; Humans; Melphalan; Multiple Myeloma; Ovarian Neoplasms; Rad51 Recombinase; Signal Transduction	2012
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:7 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult	2013
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer medicine, 2013, Volume: 2, Issue:4 Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Gemcitabine; Immunologic Memory; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Melphalan; Mice; Myeloid Cells; Neoplasms; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory	2013
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer research, 2014, Jul-01, Volume: 74, Issue:13 Topics: Animals; Antineoplastic Agents, Alkylating; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Immunosuppression Therapy; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphocyte Activation; Lymphoma; Melphalan; Mice; Mice, Inbred BALB C; Myeloid Cells; Programmed Cell Death 1 Receptor; Receptors, CCR2	2014
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2015, Volume: 31, Issue:8 Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Fibrinogen; Gemcitabine; Humans; Hyperthermia, Induced; Integrin beta3; Male; Melphalan; Middle Aged; Mitomycin; Peritoneal Neoplasms; Platelet Count; Platelet Glycoprotein GPIb-IX Complex; Young Adult	2015
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer]. Voprosy onkologii, 2015, Volume: 61, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines	2015
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia & lymphoma, 2016, Volume: 57, Issue:11 Topics: Adult; Antineoplastic Agents; Apoptosis; Bortezomib; Busulfan; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Membrane Potential, Mitochondrial; Middle Aged; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer, 2016, 09-01, Volume: 122, Issue:17 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult	2016
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leukemia & lymphoma, 2017, Volume: 58, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured	2017
Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Count; Male; Melphalan; Recurrence; Retrospective Studies; Young Adult	2017
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma. The Lancet. Haematology, 2017, Volume: 4, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous	2017
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. American journal of hematology, 2020, Volume: 95, Issue:4 Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine	2020
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Experimental hematology, 2020, Volume: 81 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides	2020
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma. Bone marrow transplantation, 2022, Volume: 57, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Melphalan; Stem Cells; Transplantation Conditioning; Transplantation, Autologous	2022